Tier 2 — strong

Effect of Coenzyme Q10 Supplementation on Cardiac Function and Quality of Life in Patients with Heart Failure: A Randomized Controlled Trial

Olivia Bodea, Eugen Radu Boia, Laura Maria Craciun, Mihaela Daniela Valcovici, Alexandru Catalin Motofelea, Andreea Mara Munteanu, Caius Glad Streian, Gheorghe Nicusor Pop, Simona Ruxanda Dragan
Journal of Clinical Medicine 2025 14(11):3675

Bibliography

PubMed
PMID 40507436
PubMed Central
PMC12155814
DOI
10.3390/jcm14113675
Funding
The formal funding statement says the research received no external funding. The acknowledgments state that Bleu Pharma covered the costs of the medications used in the study and Victor Babes University of Medicine and Pharmacy supported publication costs.
Competing interests
The authors declared no conflicts of interest.

Study snapshot

DesignProspective randomized double-blind placebo-controlled parallel trial
ModelAdults with NYHA class II-III heart failure receiving standard therapy were randomized to CoQ10 or placebo.
Sample120 randomized: 60 CoQ10 and 60 placebo.
InterventionCoQ10 60 mg twice daily (120 mg/day) versus identical placebo for six months, with both groups continuing standard heart-failure therapy.
Duration6 months
EndpointsGlobal longitudinal strain; Left ventricular ejection fraction; NT-proBNP; 6-minute walk distance; Minnesota Living with Heart Failure Questionnaire; Blood pressure; Heart-failure rehospitalization; Renal function

What the study showed, in plain terms

This 2025 randomized double-blind trial enrolled 120 adults with NYHA class II-III heart failure and tested CoQ10 120 mg/day versus placebo for six months on top of standard therapy.

The CoQ10 group showed better global longitudinal strain, lower NT-proBNP and greater 6-minute walk distance at six months. LVEF rose from 38.9% to 40.6% in the CoQ10 group but that change was not statistically significant (p=0.170).

The findings support a possible functional and myocardial-strain benefit, but they do not establish reduced mortality or hospitalization. A notable baseline imbalance in statin use and medication-cost support from Bleu Pharma are relevant when weighing the result.

Key findings

Global longitudinal strain improved from -11.7% to -14.9% in the CoQ10 group; p<0.001.

NT-proBNP at six months: 815.6 pg/mL CoQ10 vs 1378.5 pg/mL placebo; p=0.012.

6-minute walk distance: 349.3 ± 100.6 m CoQ10 vs 267.0 ± 96.5 m placebo; p=0.008.

LVEF increased from 38.9% to 40.6% in the CoQ10 group but the reported change was not statistically significant (p=0.170).

Baseline statin use differed materially between groups: 48% CoQ10 vs 77% placebo (p=0.001), an important imbalance for interpretation.

What this study can and cannot tell us

The trial was relatively small and lasted only six months; it was not powered to establish effects on mortality or major heart-failure hospitalization outcomes.

Several key outcomes were surrogate or functional measures rather than hard clinical events.

There was a significant baseline imbalance in statin use, which may reflect imperfect balance despite randomization.

The formal funding statement reports no external funding, but the acknowledgments state that Bleu Pharma covered medication costs; this product-related support is relevant context.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology